Will Ozempic help me drink less or reduce drug cravings?

Some people taking GLP-1 medications (like semaglutide, the active ingredient in Ozempic and Wegovy) report reduced alcohol consumption and diminished cravings for other substances. This has been confirmed in human studies for alcohol. For other substances — cocaine, opiates, amphetamines, nicotine — the evidence is currently from animal research only, not human clinical trials. GLP-1 medications are not approved for addiction treatment in Australia. If you are managing a substance use issue alongside your weight, mention both to your GP — they are relevant to each other, and your GP can explore what evidence-based support looks like for your situation.

What is the lateral septum and why does it matter for addiction?

The lateral septum is a brain region historically associated with emotional regulation that has recently attracted attention for its role in reward processing. It contains a high density of GLP-1 receptors — the same receptors targeted by medications like Ozempic — and communicates with dopamine-producing regions involved in craving and reward. New research suggests that GLP-1 activation in the lateral septum may reduce reward-seeking behaviour across multiple substances, not just food. This could explain why some people taking GLP-1 medications for weight management also notice changes in their relationship with alcohol or other substances.

Why Ozempic may curb addictions — the brain mechanism explained

What just happened

For a couple of years now, a pattern has been emerging in the clinical literature and in patient-reported experience: people taking GLP-1 receptor agonists — the class of medications that includes Ozempic (semaglutide) and Wegovy — report drinking less alcohol, feeling less drawn to cigarettes, finding cocaine less compelling. The effect was reproducible enough to generate significant research interest, but the mechanism remained poorly understood.

A new piece in The Conversation Australia, published 21 June 2026 by University of Otago researcher Robert Munn, walks through the neuroscience that is beginning to explain why.

The short version: the brain’s lateral septum — a region previously associated mostly with emotional regulation — appears to be the key. It is dense with GLP-1 receptors. And when GLP-1 receptors in that region are activated, the reward signal those circuits send to dopamine-producing brain regions appears to be dampened — not just for food, but across a broader range of reward-seeking behaviours including substance use.

The both-and

The mechanism is genuinely interesting

The lateral septum is not where most people would have looked first. It has historically been understood as an emotional-regulation structure — part of the limbic system, involved in fear, anxiety, and social behaviour. But more recent research has revealed it as something closer to a reward-processing hub.

It receives spatial and temporal information from the hippocampus — the brain’s memory structure — and annotates that information with reward value. It tracks where you were, when you were there, and how rewarding that experience was. It then relays that information to dopamine-producing brain regions that drive craving and motivation. The lateral septum, in this framework, functions as the brain’s reward-context processor — the region that turns a memory into a craving.

And it is loaded with GLP-1 receptors. When those receptors are activated, recent animal research suggests the circuit’s output is reduced: the reward signal sent downstream to dopamine regions is dampened. The mouse drinks less. The rat finds cocaine less compelling.

In humans, the alcohol finding has been replicated: people taking semaglutide consume less alcohol. This is now observed data, not just anecdote. The question is no longer whether GLP-1 medications affect alcohol consumption, but how reliably and in whom.

Where the evidence stops

For substances beyond alcohol, the evidence is currently preclinical. Cocaine, opiates, amphetamines, nicotine — reduced consumption has been demonstrated in animal models. That is a meaningful signal. It is not human trial data.

The author of the Conversation piece, Robert Munn, is based at the University of Otago in New Zealand. The research he reviews is largely international, with no Australia-specific trial data. The TGA has not approved any GLP-1 medication for the management of substance use disorders. Using semaglutide specifically for addiction treatment in Australia falls outside the approved indication — that is worth stating clearly.

There is also a population-level question the mechanism alone cannot answer: GLP-1 medications do not uniformly reduce substance cravings in all users. The individual variability is significant. Understanding who responds, and why, requires properly designed human trials that have not yet been completed.

My two cents

Two things worth holding simultaneously here.

First: if you are already taking a GLP-1 medication for weight management and you notice a change in your relationship with alcohol or other substances — reduced craving, reduced consumption, reduced pull toward a habitual pattern — that observation is clinically relevant. Tell your GP. It may be worth documenting, and it is relevant to understanding how these medications are working for you as a whole person, not just as a body weight number.

Second: this research is not a reason to request or self-administer a GLP-1 medication for addiction management. The evidence base for that specific application does not yet exist in humans beyond alcohol. The addiction medicine pathway in general practice involves evidence-based structured support — and your GP is the right starting point for that conversation, regardless of what GLP-1 medications may or may not eventually contribute.

The lateral septum finding is a genuine scientific advance. It explains something real. But it is the beginning of a research programme, not the end of one.

Verdict: maybe — watch this.

Sources cited

“Weight-loss drugs like Ozempic could work for addiction too — and we finally know how” — Robert Munn, University of Otago. The Conversation Australia, 21 June 2026. https://theconversation.com/weight-loss-drugs-like-ozempic-could-work-for-addiction-too-and-we-finally-know-how-285227
RACGP — addiction medicine resources. https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/addiction
Therapeutic Goods Administration. https://www.tga.gov.au